Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (01349) announced its monthly return on movements in securities for February 2026. The registered share capital remained unchanged at 326.00 million H shares and 710.57 million A shares, maintaining a total registered share capital of RMB 103.66 million.

According to the announcement, the number of H shares in issue stood at 326.00 million with no treasury shares held, while the A shares on the STAR Market of the Shanghai Stock Exchange remained at 710.57 million. The company confirmed that it complied with the applicable public float requirement for its H shares as of the end of February 2026. No share options, warrants, or convertible securities were outstanding, and there were no other arrangements for share issuance noted during the reporting period.